<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33317">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01716819</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A00574-39</org_study_id>
    <nct_id>NCT01716819</nct_id>
  </id_info>
  <brief_title>Role of the Renin Angiotensin Aldosterone System in the Mechanisms of Transition to Heart Failure in Abdominal Obesity</brief_title>
  <acronym>R2C2-II</acronym>
  <official_title>Role of the Renin Angiotensin Aldosterone System and Remodeling of the Matrix Cardiac Extra Cellular in the Mechanisms of Transition to Heart Failure in Abdominal Obesity: Prospective Longitudinal Study R2C2 II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      R2C2 study has shown that abdominal obesity is associated with a cardiac and vascular
      remodelling in healthy volunteers. This remodelling is correlated with renin-angiotensin
      aldosterone system (RAAS) activation and/or systemic fibrosis. R2C2 II study is designed to
      confirm the hypothesis that RAAS is associated with an early remodelling and implicated in
      the transition to cardiac failure in abdominal obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follow up of abdominal obesity patients from the R2C2 cohort  study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>cardiac extracellular matrix remodelling</measure>
    <time_frame>3-7 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Initial values of cardiac extracellular matrix remodelling biomarkers and the evolution of biomarkers at 3-7 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac and arterial phenotype</measure>
    <time_frame>3-7 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evolution of cardiac and vascular phenotype in 3-7 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Obesity, Abdominal</condition>
  <arm_group>
    <arm_group_label>Abdominal obesity</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm, follow up cohort in patient with abdominal obesity. No comparator: description of interventions :
Composition of body mass by Dual x-ray absorptiometry Pulse wave velocity Electrocardiogram Urine sample Blood sample (and biological collection) Assessment of sleep apnea syndrome Glucose tolerance test Echocardiography Echotracking cardiac and abdominal magnetic resonance imaging Ambulatory blood pressure monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urine sample</intervention_name>
    <description>dosages on one spot and 24h collection</description>
    <arm_group_label>Abdominal obesity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>dosages</description>
    <arm_group_label>Abdominal obesity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessment of sleep apnea syndrome</intervention_name>
    <arm_group_label>Abdominal obesity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrocardiogram</intervention_name>
    <arm_group_label>Abdominal obesity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose tolerance test</intervention_name>
    <arm_group_label>Abdominal obesity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <arm_group_label>Abdominal obesity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cardiac and abdominal magnetic resonance imaging</intervention_name>
    <arm_group_label>Abdominal obesity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ambulatory blood pressure monitoring</intervention_name>
    <arm_group_label>Abdominal obesity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echotracking</intervention_name>
    <arm_group_label>Abdominal obesity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulse wave velocity</intervention_name>
    <arm_group_label>Abdominal obesity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Composition of body mass by Dual x-ray absorptiometry</intervention_name>
    <arm_group_label>Abdominal obesity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Being a former member of R2C2 study, abdominal obese group.

          -  Having signed the informed consent (refusing to participate to the genetic study is
             not an exclusion criteria).

          -  being affiliated to health insurance scheme.

        Inclusion Criteria of R2C2 study:

          -  Men and women aged between 40 and 65 year's old

          -  Caucasian

          -  Born or living in France for at least 10 years

          -  Presenting an abdominal obesity defined by a waist circumference &gt;94 cm in men and ≥
             80 cm in women, associated or not with untreated hypertension or hypertension treated
             for less than one year

          -  Having signed the informed consent

        Exclusion Criteria:

          -  Subjects unable to understand the information letter

          -  Subjects under supervision or guardianship

          -  pregnant or lactating woman

          -  A contraindication to perform MRI is not an exclusion criteria.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>43 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick ROSSIGNOL</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC-P - INSERM - Institut Lorrain du Cœur et des vaisseaux Louis Mathieu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick ROSSIGNOL</last_name>
    <phone>+33383157320</phone>
    <email>p.rossignol@chu-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Faiez ZANNAD</last_name>
    <phone>+33383157320</phone>
    <email>f.zannad@chu-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIC-P - INSERM - Institut Lorrain du Cœur et des vaisseaux</name>
      <address>
        <city>Vandoeuvre Lès Nancy</city>
        <state>Meurthe et Moselle</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick ROSSIGNOL</last_name>
      <phone>+33 3 83 15 73 20</phone>
      <email>p.rossignol@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Faiez ZANNAD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Yves MARIE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc BOIVIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela DOBRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José MEDINA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien MANDRY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wassila DJABALLAH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cédric PASQUIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques FELBLINGER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne PIZARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno GUERCI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe BOHME</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>October 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure, abdominal obesity, RAAS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
